Old boatProfound Medical $PROF
Grew revenue 50.7% in FY2025 to $16 million, operating margin -256% against a 1.2% median for surgical & medical instruments & apparatus, equity 85.7% of assets.
Last filing8-K · Item 1.01 Entry into a Material Definitive Agreement, 3 Nov 2026
Edgarette’s full reading · exposure, experience, soundness, credibility, range
🫧 Edgar looked up PROFOUND MEDICAL CORP. ($PROF). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-11-03. 38 event filings (8-K) in the past twelve months. Non-reliance (8-K Item 4.02) filed 2025-03-07.
🔖 Exposure: revenue $16.1M (FY2025), total debt $4.5M. Experience: revenue up 50.7% on the year, up 49.5% a year over 2 years; operating margin -256.3%, up from -309.6%. Soundness: equity 85.7% of assets, return on equity -64.1%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $17.7M and $31.8M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -256.3% against a 1.2% median; growth 50.7% against 11.6%.
Read from its own SEC filings · nothing written, nothing inferred
Speed and cash · fiscal 2025
Both views must agree for a label · a description, not advice.
| Cash flow (op · inv · fin · free) | −$38M · −$0M · $41M · −$38M |
| Investment book (cash · short · long) | $60M · — · — · current ratio 12.52 |
| Revenue swing · equity of assets | 1.1% · 85.8% |
Profound Medical is growing faster than its size class, with steadier revenue. Its own audited SEC figures.
The figures, as filed
| Fiscal year end | 2025-12-31 |
| Revenue | $16M |
| Revenue, on the year | 50.7% |
| Revenue, a year over the record | 49.5% |
| Operating margin | −256.3% |
| Operating margin, prior year | −309.6% |
| Net margin | −264.4% |
| Research and development | $21M · 127.9% of revenue |
| Total debt | $4M |
| Equity of assets | 85.7% |
| Return on equity | −64.1% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $1.41 |
| Book value per share | $2.20 |
| Revenue per share | $0.53 |
| Shares outstanding | 30,232,966 |
| Audited years read | 3 |
Peers: the median of 60 filers with $50M+ revenue in surgical & medical instruments & apparatus.
Classic signals · fiscal 2025Altman Z″ -3.44 distress zone 1968Piotroski F 4 of 9 middling 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals -5.9% earnings backed by cash 1996DuPont ROE -67.1% = margin -264.4% × turns 0.22 × leverage 1.16
What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →
Health HarborProfound Medical sails as: Old boat
Health watch · 12 monthsDirector or officer change ×3
Sailing speed follows growth: 50.7% a year crosses the harbor in 30 seconds.
🌊 Visit the Bay →- operating cash flow was negative
- operating loss: a margin of -256.3% in FY2025
- revenue is hard to predict: its 80% range is ±28%
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
- 8-K · 2026-11-03 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 8-K · 2026-10-22 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 8-K · 2026-10-14 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 8-K · 2026-10-09 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
- 8-K · 2026-10-07 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits
- 8-K · 2026-09-04 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company